{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06524687",
            "orgStudyIdInfo": {
                "id": "IGM-2323-103"
            },
            "organization": {
                "fullName": "IGM Biosciences, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies",
            "officialTitle": "A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Adult Participants With Active, Refractory Moderate-Severe Idiopathic Inflammatory Myopathies",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "a-study-of-imvotamab-in-active-refractory-idiopathic-inflammatory-myopathies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-23",
            "studyFirstSubmitQcDate": "2024-07-26",
            "studyFirstPostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "IGM Biosciences, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.\n\nParticipants will be given imvotamab through a vein (i.e., intravenously).",
            "detailedDescription": "This is a Phase 1b, open-label study to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of imvotamab in adult participants with active, refractory, moderate-severe Idiopathic Inflammatory Myopathies. Approximately 5-10 participants will be assigned."
        },
        "conditionsModule": {
            "conditions": [
                "Idiopathic Inflammatory Myopathies",
                "Inflammatory Myopathies"
            ],
            "keywords": [
                "Myopathies",
                "Moderate-Severe Myopathy",
                "Myositis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Imvotamab (Dose Escalation)",
                    "type": "EXPERIMENTAL",
                    "description": "Imvotamab administered intravenously",
                    "interventionNames": [
                        "Drug: Imvotamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Imvotamab",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Imvotamab (Dose Escalation)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability of imvotamab",
                    "description": "Incidence of adverse events (AEs), serious adverse events (SAEs), including serious",
                    "timeFrame": "Time Frame: Up to Week 50"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \u2265 18 years at the time of signing ICF\n* Diagnosis of probable or definite IIM according to the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for IIM with subgroup classification of either DM, polymyositis (PM), anti-synthetase syndrome, or immune-mediated necrotizing myositis (IMNM).\n* Active IIM despite treatment with corticosteroids and at least 1 immunosuppressive or immunomodulatory standard-of-care agent determined at the discretion of the investigator after at least 3 months of treatment.\n* If using oral corticosteroids (OCS), must be on a stable dose equivalent to \u2264 30 mg/day of prednisone for at least 4 weeks prior to first study treatment\n\nKey Exclusion Criteria:\n\n* Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of imvotamab.\n* Receipt of an investigational therapy less than 12 weeks or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study.\n* Has inclusion body myositis or myositis-associated with other connective tissue disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials",
                    "role": "CONTACT",
                    "phone": "(877) 544-6728",
                    "email": "IGM-2323-103@igmbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rebecca Kunder",
                    "affiliation": "IGM Biosciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Standford University",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94306",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-103@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D000009220",
                    "term": "Myositis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D000009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12092",
                    "name": "Muscular Diseases",
                    "asFound": "Myopathy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12172",
                    "name": "Myositis",
                    "asFound": "Idiopathic Inflammatory Myopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12097",
                    "name": "Musculoskeletal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12411",
                    "name": "Neuromuscular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3040",
                    "name": "Inclusion Body Myositis",
                    "asFound": "Inflammatory Myopathies",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3001",
                    "name": "Idiopathic Inflammatory Myopathy",
                    "asFound": "Idiopathic Inflammatory Myopathies",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC05",
                    "name": "Musculoskeletal Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}